The Fly | GNPX

Unique Oncolytic Adenovirus Platform: Genprex's lead candidate, DNX-2401, is a proprietary, replication-competent oncolytic adenovirus designed for both direct tumor lysis and robust immune system activation.

Advanced Clinical Development Stage: DNX-2401 is currently in Phase 2 clinical trials for recurrent glioblastoma, signifying significant progress beyond preclinical research and early-stage development.

Dual Mechanism of Action: The therapy operates through a powerful two-pronged approach, directly destroying cancer cells while simultaneously stimulating a systemic anti-tumor immune response, potentially enhancing efficacy.

Clinical Trial Outcomes Risk: Failure of ongoing or future clinical trials to meet primary or secondary endpoints or demonstrate sufficient safety and efficacy for regulatory approval.

Regulatory Approval Hurdles Risk: Inability to obtain necessary regulatory approvals from agencies like the FDA, even if clinical trials are successful, due to unforeseen concerns or data interpretation.

Capital and Funding Risk: Insufficient access to additional capital, leading to potential operational delays, reduction in R&D activities, or significant shareholder dilution through equity offerings.

Charts

Clinical Trial Outcomes Risk: Failure of ongoing or future clinical trials to meet primary or secondary endpoints or demonstrate sufficient safety and efficacy for regulatory approval.